


Singapore's UltraGreen.ai accelerates global adoption of fluorescence-guided surgery quantification

17 June 2025 | News | By Hithaishi C Bhaskar

A comprehensive surgical intelligence platform designed by combining advanced data and imaging infrastructure with Perfusion Tech's validated clinical quantification engine



UltraGreen.ai, a Singapore-headquartered leader in surgical imaging technology, announced the acquisition of Perfusion Tech, a clinical software innovator focused on real-time perfusion quantification during surgical procedures.

This strategic acquisition positions UltraGreen at the forefront of fluorescence guided surgery (FGS) by combining UltraGreen's fluorescence imaging products with Perfusion Tech's validated clinical quantification engine

A comprehensive surgical intelligence platform enables standardised, objective, reproducible perfusion assessments in intraoperative imaging, resulting in safer, more accurate surgical outcomes.

UltraGreen's ecosystem is anchored by its flagship products Verdye™ and IC-Green®, the world's leading indocyanine green (ICG) fluorescence agents, managed globally by Diagnostic Green. The integration of Perfusion Tech's quantification software creates a complete fluorescence platform that provides:

- Real-time visualisation of blood flow during surgery
- Quantitative analytics that help remove subjective interpretation
- Cloud-based data management for improved workflow
- AI-powered insights that build robust datasets to support future driven insights

Ravi Sajwan, Co-CEO of UltraGreen.ai said "With Perfusion Tech's platform, we are unlocking a new layer of insights—bringing scalable, quantitative intelligence to procedures where precision is critical, from colorectal and

reconstructive surgery to the diabetic ulcer market and beyond. We're creating technology that enables surgeons to make more precise, data-driven decisions during critical procedures, which directly translates to better patient outcomes and more efficient healthcare delivery.”

The acquisition also paves the way for UltraGreen's expansion into vascular medicine and chronic wound care— including the diabetic foot ulcer market, where impaired perfusion is a key driver of poor healing outcomes and limb amputation. At present there are over 18 million patients suffering globally from diabetic foot ulcers. As diabetic incidence continues to grow globally, the demand for real-time, non-invasive perfusion measurement offers a practical solution for early assessment and ongoing monitoring in both hospital and outpatient settings.